The Use of Driving Impairing Medicines: a European Survey

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2009 Jul 22

PMID 19621220

Citations 16

Authors

Silvia Ravera

Sylvia A Hummel

Pieter Stolk

Rob E Heerdink

Lolkje T W de Jong-van den Berg

Johan J de Gier

Affiliations

Soon will be listed here.

Abstract

Aim: To analyse the consumption of a number of medicines with a known potential for increasing the risk of road traffic accidents in the general population of Europe.

Methods: Questionnaires were distributed through the European Drug Utilization Research Group (EuroDURG) and Post-Innovation Learning through Life-events of drugs (PILLS) networks. A total of 30 countries (the current EU Member States, Iceland, Norway and Switzerland) were asked to supply data on the use of driving impairing medicines for the period 2000-2005, aggregated at the level of the active substance and presented in Defined Daily Doses (DDDs) per 1000 inhabitants per day.

Results: National utilization data were provided by 12 of the 30 countries. Based on these data, a considerable increase in consumption was only seen for the antidepressants and the selective serotonin reuptake inhibitors. A slight increase, decrease or no increase was seen for the rest of the drugs studied (i.e. opioids, antipsychotics, anxiolytics, hypnotics and sedatives, drugs that are used in addictive disorders and antihistamines). Limitations were encountered when data on driving impairing medicines were compared between countries (e.g. variation in the data sources and providers, population coverage, inclusion of hospital data, use of divergent ATC/DDD versions) and, therefore, a cross-national comparison could not be performed.

Conclusions: During the study period, trends within countries showed slight to no increase in the consumption of selected medicinal drug groups, with the exception of the antidepressants and the selective serotonin reuptake inhibitors: they showed a remarkable increased use during the study time-frame. Our results illustrate that it is still difficult to perform a valid and comprehensive collection of drug utilization data on driving impairing medicines. Therefore, efforts to harmonize data collection techniques are required and recommended.

Citing Articles

Effectiveness of road safety interventions: An evidence and gap map.

Goel R, Tiwari G, Varghese M, Bhalla K, Agrawal G, Saini G Campbell Syst Rev. 2024; 20(1):e1367.

PMID: 38188231 PMC: 10765170. DOI: 10.1002/cl2.1367.

Trends in the Use of Driving-Impairing Medicines According to the DRUID Category: A Population-Based Registry Study with Reference to Driving in a Region of Spain between 2015 and 2019.

Gutierrez-Abejon E, Criado-Espegel P, Pedrosa-Naudin M, Fernandez-Lazaro D, Herrera-Gomez F, Alvarez F Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111265 PMC: 10145018. DOI: 10.3390/ph16040508.

Assessment of Potentially Inappropriate Medications Using the EU (7)-PIM List, in a Sample of Portuguese Older Adults' Residents in Nursing Homes.

Placido A, Aguiar A, Pineiro-Lamas M, Varallo F, Figueiras A, Herdeiro M Risk Manag Healthc Policy. 2022; 15:1343-1352.

PMID: 35860675 PMC: 9289568. DOI: 10.2147/RMHP.S346300.

Medication Evaluation in Portuguese Elderly Patients According to Beers, STOPP/START Criteria and EU(7)-PIM List - An Exploratory Study.

Monteiro C, Canario C, Ribeiro M, Duarte A, Alves G Patient Prefer Adherence. 2020; 14:795-802.

PMID: 32440104 PMC: 7211315. DOI: 10.2147/PPA.S247013.

The relationship between illnesses and medical drug consumption with the occurrence of traffic accidents among truck and bus drivers in Tehran, Iran.

Khoshakhlagh A, Yazdanirad S, Laal F, Sarsangi V Chin J Traumatol. 2019; 22(3):142-147.

PMID: 31056467 PMC: 6543181. DOI: 10.1016/j.cjtee.2019.01.009.

References

Del Rio M, Gomez J, Sancho M, Alvarez F . Alcohol, illicit drugs and medicinal drugs in fatally injured drivers in Spain between 1991 and 2000. Forensic Sci Int. 2002; 127(1-2):63-70. DOI: 10.1016/s0379-0738(02)00116-0. View

Furst J, Kocmur M . Use of psychiatric drugs in Slovenia in comparison to Scandinavian countries. Pharmacoepidemiol Drug Saf. 2003; 12(5):399-403. DOI: 10.1002/pds.826. View

Barbone F, McMahon A, Davey P, Morris A, Reid I, McDevitt D . Association of road-traffic accidents with benzodiazepine use. Lancet. 1998; 352(9137):1331-6. DOI: 10.1016/s0140-6736(98)04087-2. View

Cooperstock R, Parnell P . Research on psychotropic drug use. A review of findings and methods. Soc Sci Med. 1982; 16(12):1179-96. DOI: 10.1016/0277-9536(82)90143-5. View

Ojaniemi K, Lintonen T, Impinen A, Lillsunde P, Ostamo A . Trends in driving under the influence of drugs: a register-based study of DUID suspects during 1977-2007. Accid Anal Prev. 2008; 41(1):191-6. DOI: 10.1016/j.aap.2008.10.011. View

Kennedy S, Lam R, Cohen N, Ravindran A . Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001; 46 Suppl 1:38S-58S. View

Bramness J, Skurtveit S, Morland J . Clinical impairment of benzodiazepines--relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug Alcohol Depend. 2002; 68(2):131-41. DOI: 10.1016/s0376-8716(02)00188-6. View

Bruce S, Vasile R, Goisman R, Salzman C, Spencer M, Machan J . Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. Am J Psychiatry. 2003; 160(8):1432-8. DOI: 10.1176/appi.ajp.160.8.1432. View

Allgulander C, Bandelow B, Hollander E, Montgomery S, Nutt D, Okasha A . WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2004; 8(8 Suppl 1):53-61. DOI: 10.1017/s1092852900006945. View

10.

Vander Stichele R, Elseviers M, Ferech M, Blot S, Goossens H . European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol. 2004; 58(4):419-28. PMC: 1884596. DOI: 10.1111/j.1365-2125.2004.02164.x. View

11.

Movig K, Mathijssen M, Nagel P, van Egmond T, de Gier J, Leufkens H . Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev. 2004; 36(4):631-6. DOI: 10.1016/S0001-4575(03)00084-8. View

12.

Hamunen K, Laitinen-Parkkonen P, Paakkari P, Breivik H, Gordh T, Jensen N . What do different databases tell about the use of opioids in seven European countries in 2002?. Eur J Pain. 2007; 12(6):705-15. DOI: 10.1016/j.ejpain.2007.10.012. View

13.

Gjerde H, Normann P, Pettersen B, Assum T, Aldrin M, Johansen U . Prevalence of alcohol and drugs among Norwegian motor vehicle drivers: a roadside survey. Accid Anal Prev. 2008; 40(5):1765-72. DOI: 10.1016/j.aap.2008.06.015. View

14.

Ronning M, Blix H, Strom H, Skovlund E, Andersen M, Vander Stichele R . Problems in collecting comparable national drug use data in Europe: the example of antibacterials. Eur J Clin Pharmacol. 2003; 58(12):843-9. DOI: 10.1007/s00228-003-0572-8. View

15.

Furtado C, Teixeira I . [Benzodiazepine's utilization in continental Portugal (1999-2003)]. Acta Med Port. 2007; 19(3):239-46. View

16.

Walsh J, de Gier J, Christopherson A, G Verstraete A . Drugs and driving. Traffic Inj Prev. 2004; 5(3):241-53. DOI: 10.1080/15389580490465292. View

17.

Skurtveit S, Christophersen A, Morland J . [Driving under the influence of benzodiazepines. Sale differences in the counties are reflected among drivers suspected of driving under the influence of a drug]. Tidsskr Nor Laegeforen. 1995; 115(2):200-3. View

18.

Divac N, Tosevski D, Babic D, Djuric D, Prostran M, Samardzic R . Trends in consumption of psychiatric drugs in Serbia and Montenegro 2000-2004. Pharmacoepidemiol Drug Saf. 2006; 15(11):835-8. DOI: 10.1002/pds.1316. View